US Patent Issued to Amgen on Aug. 18 for "Immunogens derived from SARS-CoV2 spike protein" (California Inventors)

ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,709,636, issued on Aug. 18, was assigned to Amgen Inc. (Thousand Oaks, Calif.).

"Immunogens derived from SARS-CoV2 spike protein" was invented by Fernando Garces (San Francisco), Zhulun Wang (Los Altos, Calif.) and Timothy Riley (Moorpark, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to severe acute respiratory syndrome coronavirus 2 ("SARS-CoV2") immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2...